On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
This is the first update to the original CTS communication distributed on July 6th. As previously co...